Arthritis is the most common nonintestinal complication for people with ulcerative colitis (UC). These tips can help stave it ...

The combination showed efficacy exceeding that of either monotherapy ...

For too long you have suffered from inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). Crohn’s disease.

IBD is an immune condition. Instead of peacefully coexisting with gut microbes, the immune system becomes overly reactive, ...

The former Rangers lefty reliever discussed his time with Texas, plus the guys break down Texas' recent struggles on offense.

Five IPO and two SPACs submitted filings. Signal processing platform HawkEye 360 priced at the top of the range to raise $416 ...

May 8 () - Odyssey Therapeutics shares rose 11.1% in its Nasdaq ‌debut on Friday, giving the ‌biopharmaceutical firm a valuation of $899.

Odyssey Therapeutics secured a valuation of $899.9 million after its ​shares rose 11.1% in their Nasdaq debut on Friday, ...

Since then, Odyssey has had no problems bringing in the megarounds. As well as the $218 million that the company launched ...

You never forget the humiliation,” says Amy Dennis as she recalls pleading with a bus driver to stop for her to use a toilet.

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Investigational New Drug (IND) application for 9MW5211, its ...

Swiss biotech Windward Bio is planning to take on some heavyweight rivals with its TSLP-acting drug for inflammatory respiratory and dermatological diseases – a mission that will be helped by adding ...